Grigg Ingeham and Liu Hanyang bank to develop new drugs for the treatment of NASH and liver disease

today, Boehringer Ingelheim and Yuhan, a South Korean pharmaceutical company, jointly announced a partnership and licensing agreement.
The two companies will work together to develop innovative double agitations for the treatment of non-alcoholic fatty hepatitis (NASH) and related liver diseases, which bring together GLP-1 and FGF21 activity in a molecule.This collaboration combines Liu Hanyang's expertise in FGF21 biology, obesity and NASH with Bollinger Ingham's pharmaceutical expertise to deliver innovative drugs to patients with cardiometabolic disease.Preclinical evidence suggests that the efficacy of the gut hormone GLP-1 was more pronounced when combined with FGF21. The double agitation (GLP1R/FGF21R astration) is expected to reduce liver cell damage and liver inflammation by eliminating fatty hepatitis and direct antifibrosis.This in-house therapy could become a potential "first-in-class" therapy, further enriching Bronger Ingham's research and development pipeline for the treatment of NASH.YoKO has been a selected partner for cardiovascular and metabolic products at Bollinger Ingham for many years. Under the terms of the agreement, YoKO will receive $40 million in advance and up-to-date payments, and will be eligible for potential milestone payments of up to $830 million, as well as a share of future sales. (Drug Information Network)